Supreme Court Judge Recused From Glivec Patent Case In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - A strongly worded letter of appeal signed by prominent IP lawyers and health activists to India's minister of law and Justice Salman Khurshid led to the surprise recusal of Supreme Court Judge Dalveer Bhandari from the controversial and long-pending Glivec (imatinib) patentability case in India
You may also be interested in...
Novartis Says Adverse Gleevec Ruling Would Impact Outlook For India
As India’s Supreme Court prepares to deliver a landmark verdict next week on the patentability of Gleevec, Novartis prepares for stormy weather.
Is India Falling Behind Its Neighbors In Attracting Clinical Research?
During the USA-India Chamber of Commerce biopharma summit, participants discussed the pros and cons of doing research in India, and pointed to key policy issues that must be resolved to spur more clinical trials.
Is India Falling Behind Its Neighbors In Attracting Clinical Research?
During the annual USA-India Chamber of Commerce biopharma summit, participants discussed the pros and cons of doing research in India, and pointed to key policy issues that must be resolved to spur more clinical trials.